Prognostic factors and outcomes of adult lymphoblastic lymphoma in the United States
Conclusions Adult patients with LL have poor long-term outcomes and novel therapies are needed. Radiotherapy had a positive impact on T-LL outcome. Teaser We retrieved data of 696 adult patients with lymphoblastic lymphoma (LL) from the SEER-18 registries (53% T-LL, 19% B-LL). Five year survival rates for B-LL and T-LL were similar (45% vs. 48%). Age, race and radiotherapy were independent prognostic factors for outcome in T-LL. Limited tumor stage, and the most recent year of diagnosis are favorable prognostic factors for B-LL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - June 7, 2017 Category: Cancer & Oncology Source Type: research

A Phase I/II Trial of Panobinostat in Combination with Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
Conclusion: Although the combination of panobinostat and lenalidomide appears safe in patients with relapsed/refractory HL, the limited efficacy and significant rates of neutropenia and febrile neutropenia observed do not support further evaluation of this combination in HL. This trial was registered at clinicaltrials.gov #NCT01460940. Teaser Based on previous studies demonstrating single agent efficacy with lenalidomide and panobinostat in patients with relapsed or refractory Hodgkin lymphoma (HL), we conducted a phase I/II study to evaluate the safety and efficacy of the combination in this patient population. The recomm...
Source: Clinical Lymphoma Myeloma and Leukemia - May 23, 2017 Category: Cancer & Oncology Source Type: research

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I
Conclusion A variety of assessment methods beyond palpable spleen length that are easily accessible in the community setting may be useful in evaluating the clinical benefit of ruxolitinib over time in patients with MF. Teaser Ruxolitinib provided clinical benefit for patients with myelofibrosis in clinical trials. However, assessing benefit in community settings remains challenging. This exploratory analysis evaluated results from the phase 3 COMFORT-I trial using practical measures (N=286). Spleen length alone was insufficient for identifying all patients receiving clinical benefit, emphasizing the importance of using mu...
Source: Clinical Lymphoma Myeloma and Leukemia - May 13, 2017 Category: Cancer & Oncology Source Type: research

Impact of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma following autologous hematopoietic cell transplantation
Conclusions A minority of cHL who achieve CR following auto-HCT will ultimately relapse. Surveillance imaging detected about half of relapses; however, outcomes were similar for those whose relapse was detected by routine surveillance imaging versus detected clinically in between surveillance imaging studies. There appears to be limited utility for routine surveillance imaging in cHL patients who achieve complete remission after auto-HCT. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - May 13, 2017 Category: Cancer & Oncology Source Type: research

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
Conclusion Carfilzomib in combination with cyclophosphamide and dexamethasone is effective and has manageable toxicity for patients with newly diagnosed MM. Teaser The CHAMPION-2 study evaluated 3 dose levels of carfilzomib when given with fixed dose oral cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma. Carfilzomib with cyclophosphamide and dexamethasone is effective and has manageable toxicity. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - May 11, 2017 Category: Cancer & Oncology Source Type: research

“Outcome and Clinical Significance of Immunophenotypic Markers Expressed in different treatment protocols of T-ALL Pediatric Patients in developing countries
Conclusion Outcome of patients with T-ALL significantly improved in patients received treatment protocol of ALL with high-risk criteria. This protocol eliminates the bad outcomes effect of several clinical and immunophenotypic markers. Patient with ETP-ALL phenotype had non-significant inferior outcome compared to non-ETPALL group. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - May 11, 2017 Category: Cancer & Oncology Source Type: research

Viral-induced hemorrhagic cystitis after allogeneic hematopoietic stem cell transplant
Conclusion The presence of the identified risk factors should prompt closer follow-up with screening tests and preventive measures for BK virus and CMV infections in patients undergoing HSCT. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - May 11, 2017 Category: Cancer & Oncology Source Type: research

Final results of a phase I study of vorinostat, pegylated liposomal doxorubicin and bortezomib in relapsed or refractory multiple myeloma
Publication date: Available online 10 May 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Peter M. Voorhees, Cristina Gasparetto, Dominic T. Moore, Diane Winans, Robert Z. Orlowski, David D. Hurd Deacetylase inhibitors have synergistic activity in combination with proteasome inhibitors and anthracyclines in preclinical models of multiple myeloma. We therefore evaluated the safety and efficacy of the deacetylase inhibitor vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib in relapsed/refractory multiple myeloma. Thirty-two patients were treated with PLD and bortezomib in combi...
Source: Clinical Lymphoma Myeloma and Leukemia - May 11, 2017 Category: Cancer & Oncology Source Type: research

Impact of Healthcare Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia
Conclusions Insurance source at diagnosis has no impact on AML treatment outcomes. The consistency of our results with some but not all studies is probably driven primarily by access to care requirements among different states. Further efforts to better understand such disparities are warranted. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - May 11, 2017 Category: Cancer & Oncology Source Type: research

Generic Imatinib in Chronic Myeloid Leukemia: Survival of the cheapest
Conclusion: The findings of the present study showed comparable efficacy and safety of the generic and innovator versions of imatinib in the treatment of patients with CML. Teaser The results of a retrospective analysis, of data from a large group patients with chronic myeloid leukemia (CML) treated with frontline Imatinib mesylate (Innovator/Generic) at a single institution between 2008 and 2014 showed comparable efficacy and safety. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - May 11, 2017 Category: Cancer & Oncology Source Type: research

Expression of peripheral blood miRNA-720 and miRNA-1246 can be used as a predictor for outcome in multiple myeloma patients.
Publication date: Available online 10 May 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Yuyue Ren, Xiaoyun Li, Wei Wang, Wanting He, Jinghua Wang, Ying Wang Multiple myeloma(MM) is a heterogeneous disorder, encompassing several related entities that share the common characteristic of being composed of monoclonal plasma cells (PCs). MicroRNAs (miRNAs) are small non-coding RNAs that control the expression of many target messenger RNAs involved in normal cell functions. Two serum microRNAs, miRNA-720 and miRNA-1246, were found to have potential as diagnostic biomarkers in myeloma. Therefore, we investigated a...
Source: Clinical Lymphoma Myeloma and Leukemia - May 10, 2017 Category: Cancer & Oncology Source Type: research

ZOH é: A prospective study of the use of biosimilar filgrastim Zarzio® in clinical practice in patients treated with chemotherapy for lymphoid malignancies
Conclusions In routine clinical practice in France, Zarzio® is mostly used as primary prophylaxis for CT-induced neutropenia in patients with haematological malignancies. Patient-related risk factors appear to have more weight in clinicians’ decisions to give Zarzio® than the FN risk category of the CT regimen alone in real-world practice. Teaser The ZOHé study showed that Zarzio® is readily used for prophylaxis of chemotherapy-induced neutropenia in France, and clinicians’ assessment of febrile neutropenia risk is driven by patient factors more than the EORTC risk category of the chemotherap...
Source: Clinical Lymphoma Myeloma and Leukemia - May 10, 2017 Category: Cancer & Oncology Source Type: research

New Agents in Multiple Myeloma: An Examination of Safety Profiles
Publication date: Available online 10 May 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sara Bringhen, Edwin De Wit, Meletios-Athanassios Dimopoulos Numerous treatments are available for relapsed and/or refractory multiple myeloma (MM), with safety profiles varying across drug classes and across agents within the same class. Thus, it is important to understand the toxicities of each antimyeloma agent when making treatment decisions. Neutropenia is commonly associated with lenalidomide and pomalidomide, and may be common with histone deacetylase (HDAC) inhibitors, but is relatively unusual with thalidomide,...
Source: Clinical Lymphoma Myeloma and Leukemia - May 10, 2017 Category: Cancer & Oncology Source Type: research

The Metabolic Syndrome in long-term survivors of Haematopoietic Stem Cell Transplantation
Publication date: Available online 10 May 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): S.C. Ragbourne, M.A. Crook Since its introduction more than fifty years ago, haematopoietic stem cell transplantation (HSCT) has transformed from an inescapably fatal procedure to one where cure from malignant and other non-malignant haematological diseases is becoming increasingly common. Nevertheless, longevity is not entirely restored. New causes of mortality have emerged; of particular importance is that of increased cardiovascular disease (CVD), related to metabolic syndrome (MS) and its components. Controversy exi...
Source: Clinical Lymphoma Myeloma and Leukemia - May 10, 2017 Category: Cancer & Oncology Source Type: research

Treatment of Peripheral T-Cell Lymphoma in Community Settings
Conclusions The significant variability in treatments used for PTCL emphasizes the lack of consensus therapy in this rarer lymphoma and calls for additional organized prospective and registry studies to evaluate comparative effectiveness. Teaser Peripheral T-cell lymphomas (PTCLs) represent a rare and heterogeneous group of malignancies which do not have consensus treatment recommendations. This retrospective review of 93 patients treated in community settings demonstrated considerable variability in treatment strategies. First-line CHOP and CHOP-like regimens were used in 74% of patients, providing 4-year overall survival...
Source: Clinical Lymphoma Myeloma and Leukemia - May 10, 2017 Category: Cancer & Oncology Source Type: research

Chronic lymphocytic leukemia patients with deletion 11q have a short time to requirement of first-line therapy, but long overall survival: results of a population-based cohort in British Columbia, Canada
Conclusions Although median TFS of 11q- patients in this cohort is short at 2.5 years, OS remains long at 14.7 years, even when the majority of patients received initial treatment without alkylators. Teaser This study documents the clinical course of 67 with high-risk CLL patients with 11q- deletion, from a Provincial CLL database. Aklylator-containing chemotherapies are thought to required to overcome the adverse prognosis associated with 11q-. However, most 11q- patients did not receive alkylators first line and had a median survival of 14.7 years, comparable to the rest of the cohort. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - May 9, 2017 Category: Cancer & Oncology Source Type: research

Increased Mutational Burden and Alterations to DNA Damage Repair Genes are Associated With Poor Prognosis and Sensitivity to PI3K-mTOR Inhibitors in Multiple Myeloma
Publication date: February 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 1, Supplement Author(s): Muntasir Mamun Majumder, David Tamborero, Pekka Anttila, Raija Silvennoinen, Juha Lievonen, Samuli Eldfors, Ashwini Kumar, Alun Parsons, Minna Suvela, Esa Jantunen, Kimmo Porkka, Caroline Heckman (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 23, 2017 Category: Cancer & Oncology Source Type: research

Integrating Molecular Genetic and Gene Expression Profiling Allows Stratification of Ultra-High Risk Myeloma
Publication date: February 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 1, Supplement Author(s): Amy Sherborne, Dil Begum, Amy Price, David Johnson, Sidra Ellis, Charlotte Smith, Fabio Mirabella, Karen Menezes, Vallari Shah, Scott Kimber, John Jones, Charlotte Pawlyn, Richard Houlston, Nigel Russell, Matthew Jenner, Gordon Cook, Alina Striha, Corinne Collett, Anna Waterhouse, Walter Gregory, David Cairns, Mark Drayson, Roger Owen, Faith Davies, Gareth Morgan, Graham Jackson, Martin Kaiser (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 23, 2017 Category: Cancer & Oncology Source Type: research

Non-overlapping Promoter and Super-enhancer Driven Processes Support Myeloma Cell Growth and Survival via Distinct Regulatory Axes
Publication date: February 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 1, Supplement Author(s): Mariateresa Fulciniti, Charles Lin, Mehmet Samur, Rick Young, Kenneth C. Anderson, Herve Avet-Loiseau, James Bradner, Nikhil Munshi (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 23, 2017 Category: Cancer & Oncology Source Type: research

Workshop
Publication date: February 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 1, Supplement (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 23, 2017 Category: Cancer & Oncology Source Type: research

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17  Abnormalities in B-Cell Acute Lymphoblastic Leukemia
Conclusion In contrast to the patients with acute myeloid leukemia, our results show that MK and CK do not play a predictive role in patients with B-ALL, but further study is required to determine whether specific changes on chromosome 17 might have prognostic value when investigated separately. Micro-Abstract The effect of monosomal karyotype (MK), complex karyotype (CK) and chromosome 17 abnormalities on prognosis in B-cell acute lymphoid leukemia (B-ALL) has not yet been established. We conducted a retrospective analysis of prognostic factors on 237 adult patients with B-ALL treated at our institution. Our results showe...
Source: Clinical Lymphoma Myeloma and Leukemia - April 11, 2017 Category: Cancer & Oncology Source Type: research

Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival
Conclusion Incidence and survival of ALK-positive ALCL varies significantly with patients' demographic characteristics as identified in our study. Treatment strategies need to be tailored accordingly to address these variations and ensure uniform access to care. Micro-Abstract We used the Surveillance, Epidemiology, and End Results database to study the incidence and survival of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. We found that the disease incidence varied significantly by age, gender, and race, whereas survival was influenced by age, race, stage, period of diagnosis, and radiotherapy. ...
Source: Clinical Lymphoma Myeloma and Leukemia - April 11, 2017 Category: Cancer & Oncology Source Type: research

Can the use of bone marrow parameters improve the efficacy of risk prediction scores in chronic myeloid leukemia in imatinib era??
Conclusion Use of BM parameters, a simple mean that is feasible in routine clinical practice could improve prognostic efficacy of Sokal score with regards to PFS, but not the OS in low and intermediate risk groups. Further research to improve sensitivity of risk scores to prognosticate CML-CP and attempts at risk directed therapy is warranted. Teaser Development of various risk scores for chronic myeloid leukemia prognostication and intensification of treatment accordingly has been an area of research. Our data confirms that by using bone marrow parameters instead of conventional peripheral blood parameters we could improv...
Source: Clinical Lymphoma Myeloma and Leukemia - March 31, 2017 Category: Cancer & Oncology Source Type: research

The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia
Conclusion Although it might be feasible to use pediatric-inspired protocols in this age group, toxicity cannot be overlooked, and the application of these protocols might require modification of drug doses or schedules relative to those used for younger children. Moreover, additional surveillance and supportive measures should be implemented to maximize benefits while minimizing toxicity. Micro-Abstract In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survi...
Source: Clinical Lymphoma Myeloma and Leukemia - March 24, 2017 Category: Cancer & Oncology Source Type: research

Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
Conclusion These data have demonstrated that, in contrast to the historically poor results with standard influenza vaccination, this novel high-dose booster vaccination strategy leads to high rates of seroprotection. Randomized controlled studies are needed to compare this novel strategy to the standard vaccination strategy. Micro-Abstract The goal of the present study was to evaluate a novel prospective influenza vaccination strategy for patients with plasma cell disorders. Fifty-one patients were treated with a 2-dose series of high-dose inactivated trivalent influenza vaccine. This vaccination strategy was well tolerate...
Source: Clinical Lymphoma Myeloma and Leukemia - March 24, 2017 Category: Cancer & Oncology Source Type: research

Myeloid Sarcoma: Presentation, Diagnosis, and Treatment
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): L. Max Almond, Maria Charalampakis, Samuel J. Ford, David Gourevitch, Anant Desai Myeloid sarcoma is an extramedullary tumor of immature granulocytic cells. It is a rare condition, most often associated with acute myeloid leukemia (AML), although in some rare cases it may present in nonleukemic patients. It should therefore be considered as a differential diagnosis of any atypical cellular infiltrate. It may occur at any site, leading to very varied clinical presentations. Diagnosis is challenging and relies on a high ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 23, 2017 Category: Cancer & Oncology Source Type: research

Elderly Patients with Chronic Myeloid Leukemia Benefit from a Dasatinib dose as Low as 20 mg
Conclusion Low-dose (e.g., ≤ 20 mg) dasatinib therapy generates an adequate molecular response in most elderly CML-CP patients without causing severe AEs. Teaser A retrospective study of elderly chronic myeloid leukemia (CML) patients aged ≥ 65 years was conducted to evaluate the efficacy and safety of low-dose dasatinib treatment. Reducing the dose of dasatinib below 100 mg/day (even to ≤ 20 mg/day) generated good responses in these patients. The doses were safe and induced rapid and deep molecular responses. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 18, 2017 Category: Cancer & Oncology Source Type: research

Multiple Myeloma: Clinical Updates from the American Society of Hematology Annual Meeting 2016
Publication date: Available online 18 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Evangelos Terpos (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 18, 2017 Category: Cancer & Oncology Source Type: research

Clinical Features and Prognosis Analysis of Hodgkin Lymphoma: A Multicenter Retrospective Study Over a Decade of Patients in China
Conclusions General clinical features were comparable with those of Western patients, whereas therapeutic outcomes were slightly inferior. The novel risk assessment model showed potential as a more powerful prognostic tool by identifying 3 subsets of patients with significantly distinct outcomes, which warrants further validations. Micro-Abstract One hundred and fifty patients with newly diagnosed Hodgkin's lymphoma at 4 medical centers over a decade were reviewed. General clinical features were comparable to western patients, while therapeutic outcomes were slightly inferior. A new risk model incorporating traditional ris...
Source: Clinical Lymphoma Myeloma and Leukemia - March 12, 2017 Category: Cancer & Oncology Source Type: research

Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients
Conclusion Although ZA did not improve OS in patients with MM; it continued to be useful to reduce skeletal events, and thus improve better quality of life for patients. Micro-Abstract To assess whether prolonged use of zoledronic acid (ZA; 4 years) improves outcome in multiple myeloma patients, we performed a clinical trial to compare the effect of 48 and 24 months of treatment. A total of 170 patients were randomly assigned to the 2 groups in the trial. Overall survival was not improved, however, the ZA group showed a reduced number of skeletal events. Thus, we suggest that ZA should be considered to be used for longer d...
Source: Clinical Lymphoma Myeloma and Leukemia - March 8, 2017 Category: Cancer & Oncology Source Type: research

Thoracic Complications in Chronic Lymphocytic  Leukemia
Conclusion Thoracic manifestations in CLL are common among hospitalized patients. Although infectious pneumonia remains most common, unusual or opportunistic infections may be increasing, and direct lung damage owing to CLL itself or to newer biologic agents are being diagnosed with lung tissue sampling. Recognition of these complications will allow earlier diagnosis, which may change management including removal of offending biologic agents or augmentation of treatment for CLL when infiltrative leukemic cells are present. Micro-Abstract Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. Patients with CL...
Source: Clinical Lymphoma Myeloma and Leukemia - March 8, 2017 Category: Cancer & Oncology Source Type: research

The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia
Conclusion Our results lead us to conclude that generic imatinib as second-line therapy does not have deleterious effects on patient outcomes. However, first-line generic imatinib showed suboptimal efficacy compared with branded imatinib. Micro-Abstract We examined the long-term clinical outcomes of patients with chronic myeloid leukemia (n = 41) receiving generic imatinib as first-line (n = 27) and second-line therapy (n = 14) in Bosnia and Herzegovina. Overall survival rates for first-line and second-line generic imatinib were 85% and 100%, respectively. For first-line generic imatinib, complete cytogeneti...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Treating Multiple Myeloma Patients with Oral Therapies
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Shaji Kumar, Ravi Vij, Stephen J. Noga, Deborah Berg, Lonnie Brent, Lawrence Dollar, Ajai Chari Recent advances have highlighted the importance of long-term, continuous treatment in multiple myeloma (MM) to improve survival. However, treatment burden continues to negatively impact the real-world duration of MM therapy, and strategies to limit the adverse impact of treatment on patient quality of life are therefore particularly important. Oral MM therapies include the immunomodulatory drugs lenalidomide, thalidomide and...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Myeloid Sarcoma: Presentation, Diagnosis and Treatment
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): L. Max Almond, Maria Charalampakis, Samuel Ford, David Gourevitch, Anant Desai Myeloid sarcoma is an extramedullary tumour of immature granulytic cells. It is a rare condition, most often associated with acute myeloid leukaemia although in some rare cases it may present in non-leukaemic patients. It should therefore be considered as a differential diagnosis of any atypical cellular infiltrate. It may occur at any site leading to very varied clinical presentations. Diagnosis is challenging and relies on a high index of ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Efficacy and safety of bendamustine and ibrutinib in previously untreated patients with Chronic Lymphocytic Leukemia – indirect comparison
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Iga Andrasiak, Justyna Rybka, Wanda Knopinska-Posluszny, Tomasz Wrobel (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Waldenstr öm Macroglobulinemia: Review of Pathogenesis and Management
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Seongseok Yun, Ariel Johnson, Onyemaechi Okolo, Stacy J. Arnold, Ali McBride, Ling Zhang, Rachid C. Baz, Faiz Anwer Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M (IgM). Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of n...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Clinical and serologic responses following a two dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial
Conclusions These data demonstrate that in contrast to historically poor results with standard influenza vaccination, this novel high-dose booster vaccination strategy leads to high rates of seroprotection. Randomized controlled studies are needed to compare this to standard vaccination strategy. Teaser The goal of the present study was to evaluate a novel prospective influenza vaccination strategy in patients with plasma cell disorders. Fifty-one patients were treated with a two dose series of high-dose inactivated trivalent influenza vaccine. This vaccination strategy was well tolerated led to very high rates of seroprot...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Thoracic Complications in Chronic Lymphocytic Leukemia (Thoracic Diseases in CLL)
Publication date: Available online 17 February 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sameer Khanijo, Pragati Tandon, Cristina P. Sison, Seth Koenig Background Chronic Lymphocytic Leukemia (CLL) is the most common lymphoproliferative disorder worldwide. While thoracic complications are frequent in CLL, only limited data exist regarding the etiologies of these complications. Methods A retrospective chart review was performed on all patients admitted to a tertiary care, CLL-referral center, with CLL and a respiratory complaint from 2001 through 2013 to categorize pulmonary complaints and diagnoses. Fi...
Source: Clinical Lymphoma Myeloma and Leukemia - February 16, 2017 Category: Cancer & Oncology Source Type: research

Clinical features and prognosis analysis of Hodgkin ’s lymphoma: A multicenter retrospective study over a decade of patients in China
Conclusions General clinical features were comparable to western patients, whereas therapeutic outcomes were slightly inferior. The novel risk assessment model showed potential as a more powerful prognostic tool by identifying 3 subsets of patients with significantly distinct outcomes, which warrants further validations. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 16, 2017 Category: Cancer & Oncology Source Type: research

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 abnormalities in B-Cell Acute Lymphoid Leukemia
Publication date: Available online 17 February 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Priya Khoral, Eshetu G. Atenafu, Kenneth J. Craddock, Aaron Schimmer, Hong Chang The impact of monosomal karyotype (MK), complex karyotype (CK) and chromosome 17 abnormalities (abnl 17) on prognosis in B-cell acute lymphoid leukemia (B-ALL) has not yet been established. We conducted a retrospective analysis of prognostic factors on 237 adult patients with B-ALL treated at our institution. Older age (>60), higher white blood cell count (>30), and abnl 17 were associated with shorter overall survival on...
Source: Clinical Lymphoma Myeloma and Leukemia - February 16, 2017 Category: Cancer & Oncology Source Type: research

Prolonged Use of Zoledronic ACID ( 4 years) Did Not Improve Outcome In Multiple Myeloma Patients
Conclusions Although ZA did not improve OS in patients with MM; continue to be useful to reduce skeletal events, thus improving better quality of life to the setting of patients. Teaser To assess were prolonged use of zoledronic acid (ZA:4 years) improves outcome in multiple myeloma (MM)patients, we performed a clinical trial, for compared the effect of 48 and 24 months.A total of 170 patients were randomly assigned, to the two groups in the trial.The overall survival was not improved. However ,ZA retain to reduce the number of skeletal events. Thus, we suggested that ZA , will be considered to be employed for longer durat...
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Whole Body MR imaging: A Useful Imaging Modality in the Management of Children with Acute Myeloid Leukemia
Conclusion Chloromas tended to show multiplicity and be presented without symptoms. The most common site of involvement was musculoskeletal system. Whole body MR imaging provided additional information that affected clinical management in children with AML. Teaser Children with acute myeloid leukemia suffer from various complications such as chloromas and disseminated infection or inflammation during their illness. As these complications tend to involve everywhere in the body, whole body MR imaging may be a useful tool in children with acute myeloid leukemia. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Systemic Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival
Conclusion Incidence and survival of ALK positive ALCL varies significantly with patients’ demographic characteristics as identified in our study. Treatment strategies need to be tailored accordingly to address these variations and ensure uniform access to care. Teaser We used the SEER database to study the incidence and survival of ALK positive ALCL. We found that the disease incidence varied significantly by age, gender and race, while survival was influenced by age, race, stage, period of diagnosis and radiotherapy. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

The Dana Farber Consortium Protocol (DFCP) for the treatment of adolescents and young adults with acute lymphoblastic leukemia: a single institution experience in Saudi Arabia
Conclusion Although it might be feasible to use pediatric-inspired protocols in this age group, toxicity cannot be overlooked, and the application of these protocols might require modification of drug doses or schedules relative to those used for younger children. Moreover, additional surveillance and supportive measures should be implemented to maximize benefits while minimizing toxicity. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Local disease control in ocular adnexal lymphoproliferative disorders: comparative outcomes of MALT versus non-MALT histologies
We present a single-center, large cohort, retrospective study of the efficacy of involved field radiation therapy (IFRT) in ocular adnexal lymphoproliferative disorders (OALDs). Failure free survival (FFS), complete remission (CR), and local, regional and distant failure were determined for 112 patients with marginal zone lymphoma of mucosa associated lymphoid tissue (MALT) OALDs (n=71) and non-MALT OALDs (n=41) cohorts. Fifty-six patients with MALT OALD and 26 patients with non-MALT OALD received IFRT only (without any planned concurrent or sequential systemic chemo- or chemo-immunotherapies). Among these OALD cohorts tre...
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients
Conclusion Our results lead us to conclude that generic imatinib as second-line therapy does not have deleterious effects on patient outcomes. However, first-line generic imatinib showed suboptimal efficacy compared to branded imatinib. Teaser We examined the long-term clinical outcomes of CML patients (n=41) receiving generic imatinib as first-line (n=27) and second-line therapy (n=14) in Bosnia and Herzegovina. OS rates for first-line and second-line generic imatinib were 85% vs. 100%, respectively. For first-line generic imatinib, CCyR was 81%. Generic imatinib as second-line therapy does not have deleterious effects on...
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States
Conclusion The diagnostic workup for PTCL in the United States varies widely and often lacks important phenotypic information to fully characterize the lymphoma. Gaps in testing of selected markers should be filled, given the impending revision to the World Health Organization classification. The accuracy of diagnosis will become increasingly important as we enter the era of targeted treatment for PTCL. Micro-Abstract With increased understanding of the unique entities of peripheral T-cell lymphoma (PTCL), subtype-specific approaches are emerging, and more precise diagnoses are becoming increasingly important. Using d...
Source: Clinical Lymphoma Myeloma and Leukemia - February 13, 2017 Category: Cancer & Oncology Source Type: research

Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy
Publication date: Available online 11 January 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sid Selim, Jerome Rey, Aude Charbonnier, Evelyne D'Incan, Bilal Mohty, Didier Blaise, Norbert Vey (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 9, 2017 Category: Cancer & Oncology Source Type: research

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy
Conclusion To the best of our knowledge, the present study is the first description of PRES associated with DA-EPOCH. The key risk factors for the development of PRES identified in our study included hypertension, fluid imbalance, electrolyte abnormalities, baseline organ dysfunction, a high tumor burden, and the presence of pre-existing CNS insults during chemotherapy, such as CNS infection. Patients with these risk factors appear to have a greater risk of developing PRES and should be monitored closely during treatment. Micro-Abstract The purpose of our study was to identify risk factors for the development of posterior ...
Source: Clinical Lymphoma Myeloma and Leukemia - February 4, 2017 Category: Cancer & Oncology Source Type: research

Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients
Conclusion WT1 expression status represents a good molecular marker of prognosis, response to treatment, and MRD monitoring. Above all, the usage of the WT1 expression level as an additional marker for more precise risk stratification of AML-NK patients could lead to more adapted, personalized treatment protocols. Micro-Abstract The aim of the present study was to test the possibility for the usage of the WT1 (Wilms tumor 1) expression level as an additional biomarker for prognosis and minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia with normal karyotype (AML-NK). We found that overexpress...
Source: Clinical Lymphoma Myeloma and Leukemia - February 2, 2017 Category: Cancer & Oncology Source Type: research